The RAGE/DIAPH1 Signaling Axis & Implications for the Pathogenesis of Diabetic Complications |
| |
Authors: | Ravichandran Ramasamy Alexander Shekhtman Ann Marie Schmidt |
| |
Affiliation: | 1.Diabetes Research Program, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA;2.Department of Chemistry, The State University of New York at Albany, Albany, NY 12222, USA; |
| |
Abstract: | Increasing evidence links the RAGE (receptor for advanced glycation end products)/DIAPH1 (Diaphanous 1) signaling axis to the pathogenesis of diabetic complications. RAGE is a multi-ligand receptor and through these ligand–receptor interactions, extensive maladaptive effects are exerted on cell types and tissues targeted for dysfunction in hyperglycemia observed in both type 1 and type 2 diabetes. Recent evidence indicates that RAGE ligands, acting as damage-associated molecular patterns molecules, or DAMPs, through RAGE may impact interferon signaling pathways, specifically through upregulation of IRF7 (interferon regulatory factor 7), thereby heralding and evoking pro-inflammatory effects on vulnerable tissues. Although successful targeting of RAGE in the clinical milieu has, to date, not been met with success, recent approaches to target RAGE intracellular signaling may hold promise to fill this critical gap. This review focuses on recent examples of highlights and updates to the pathobiology of RAGE and DIAPH1 in diabetic complications. |
| |
Keywords: | RAGE DIAPH1 interferon pathway diabetes diabetic complications small molecule antagonist diabetic kidney disease diabetic accelerated atherosclerosis |
|
|